Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Cardiac Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
PLoS One. 2021 Mar 23;16(3):e0249043. doi: 10.1371/journal.pone.0249043. eCollection 2021.
We sought to investigate the impact of the COVID-19 pandemic and the Tele-HF Clinic (Tele-HFC) program on cardiovascular death, heart failure (HF) rehospitalization, and heart transplantation rates in a cohort of ambulatory HF patients during and after the peak of the pandemic.
Using the HF clinic database, we compared data of patients with HF before, during, and after the peak of the pandemic (January 1 to March 17 [pre-COVID], March 17 to May 31 [peak-COVID], and June 1 to October 1 [post-COVID]). During peak-COVID, all patients were managed by Tele-HFC or hospitalization. After June 1, patients chose either a face-to-face clinic visit or a continuous tele-clinic visit.
Cardiovascular death and medical titration rates were similar in peak-COVID compared with all other periods. HF readmission rates were significantly lower in peak-COVID (8.7% vs. 2.5%, p<0.001) and slightly increased (3.5%) post-COVID. Heart transplant rates were substantially increased in post-COVID (4.5% vs. peak-COVID [0%], p = 0.002). After June 1, 38% of patients continued with the Tele-HFC program. Patients managed by the Tele-HFC program for <6 months were less likely to have HF with reduced ejection fraction (73% vs. 54%, p = 0.005) and stage-D HF (33% vs. 14%, p = 0.001), and more likely to achieve the target neurohormonal blockade dose (p<0.01), compared with the ≥6-month Tele-HFC group.
HF rehospitalization and transplant rates significantly declined during the pandemic in ambulatory care of HF. However, reduction in these rates did not affect subsequent 5-month hospitalization and cardiovascular mortality in the setting of Tele-HFC program and continuum of advanced HF therapies.
我们旨在研究 COVID-19 大流行期间和之后,在一个门诊心力衰竭患者队列中,远程 HF 诊所(Tele-HFC)计划对心血管死亡、心力衰竭(HF)再住院和心脏移植率的影响。
使用 HF 诊所数据库,我们比较了大流行前(1 月 1 日至 3 月 17 日[COVID-19 前]、3 月 17 日至 5 月 31 日[COVID-19 高峰]和 6 月 1 日至 10 月 1 日[COVID-19 后])、高峰期间和高峰后 HF 患者的数据。在 COVID-19 高峰期间,所有患者均通过 Tele-HFC 或住院接受管理。6 月 1 日之后,患者可选择面对面诊所就诊或持续远程诊所就诊。
COVID-19 高峰期间心血管死亡和药物滴定率与所有其他时期相似。HF 再入院率在 COVID-19 高峰期间显著降低(8.7%比 2.5%,p<0.001),之后略有增加(3.5%)。心脏移植率在 COVID-19 后显著增加(4.5%比 COVID-19 高峰[0%],p=0.002)。6 月 1 日之后,38%的患者继续参与 Tele-HFC 计划。接受 Tele-HFC 治疗<6 个月的患者射血分数降低型心力衰竭(73%比 54%,p=0.005)和心力衰竭 stage-D(33%比 14%,p=0.001)的比例较低,并且更有可能达到目标神经激素阻断剂量(p<0.01),与≥6 个月的 Tele-HFC 组相比。
在 HF 的门诊治疗中,大流行期间 HF 再住院和移植率显著下降。然而,在 Tele-HFC 计划和先进 HF 治疗连续性的背景下,这些比率的降低并未影响随后的 5 个月住院和心血管死亡率。